Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Finds Reproductive Health Effects From Low Doses Of Bisphenol-A
New research from North Carolina State University and the National Institute of Environmental Health Sciences (NIEHS) shows significant reproductive health effects in rats that have been exposed to bisphenol-A (BPA) at levels equivalent to or below the dose that has been thought not to produce any adverse effects.

FDA Approves VYVANSE CII Label Change To Include Supplementary Clinical Data Supporting Efficacy At 13 Hours Postdose In Children Age 6-12 With ADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients included in its product labeling.
News of the day
Transparency In Medical Research And Education
U.S. Senators Mel Martinez (R-FL) and Herb Kohl (D-WI) of the Special Committee on Aging held a hearing to address the issue of transparency in physician-industry financial relationships. Among the hearing"s topics were the industry"s involvement in continuing medical education and its potential use as a method for promoting "off-label" prescribing. The senators heard from witnesses about different ways to achieve balance between appropriate industry involvement in continuing medical education while mitigating unethical and illegal promotion.
Diagnostics

Hampton Court Allergy Screening A Success, UK

The National Pharmacy Association and Allergy UK provided free allergy screening to the public at Hampton Court Palace Flower Show from 7-12 July. Over 7,000 members of the public picked up information on community pharmacy allergy screening or asked for advice and 75 allergy screenings were carried out. Jules Payne, Deputy Chief Executive, Allergy UK said: "Allergy UK has done a lot of shows over the years and, without a doubt, this was the best show we have ever done. A lot of the people we spoke to clearly had very real allergic/intolerant problems. Even though people were out for a nice day out, it proved added value to them. People were also picking up the information for their friends and family." Stephen Foster, Community Pharmacist (Pierremont Pharmacy, Broadstairs, Kent) said: "Allergy screening was very well received by the public at Hampton Court and the event has proved to be a successful way of raising the profile of the service. I would like to see pharmacy engaged with more events like this in the future." John Turk, Chief Executive, National Pharmacy Association said: "Hampton Court Palace Flower Show gave us the opportunity to engage with the public about community pharmacy allergy screening on our members behalf. The community pharmacy service has been running just about year so we wanted an event to showcase the service where we could put into practice what pharmacy is all about - speaking with the public face to face." "The Show has proved that there is clearly a demand for allergy screening at primary care level. The feedback, from those who talked to us at Hampton Court, was that community pharmacy is the right place to help people with their allergies." The National Pharmacy Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009